Prokarium

History shows us that those who dare to think differently shape the future 💡   Take William Coley, for example—a pioneering surgeon in the 1890s who made groundbreaking discoveries by exploring the link between infection and cancer remission by injecting bacterial toxins into cancer patients. Although his approach was unconventional and met with severe skepticism, fast forward 100 years and live bacteria BCG remains the standard-of-care in bladder cancer. Prokarium wants to celebrate trailblazers in our industry who push boundaries and redefine what’s possible. #Immunotherapy #BCG #BladderCancer

🚀 Bladder Cancer Market Insight Series: Week 4 As we wrap up our series, we're excited to highlight the groundbreaking work Prokarium is doing to redefine the treatment paradigm for bladder cancer. Our lead program, a testament to our team’s dedication, is currently advancing in Phase 1 clinical trials in the US. This milestone brings us one step closer to delivering innovative treatments that could significantly improve patient outcomes and quality of life. Thank you for sharing all your positive thoughts throughout this series! Together, we can make a difference. #BladderCancer #Oncology #Immunotherapy #ClinicalTrials

🎉 BIA Summer party 🎉 This July, the Prokarium team joined other members of the UK life science community for the annual BIA Summer Party. Thanks to the BioIndustry Association (BIA) for hosting such a great event! We are already looking forward to next year. #Prokarium #BIASummerParty #Networking #Biotech

🚀 Bladder Cancer Market Insight Series: Week 3   This week, we're shedding light on some crucial challenges in the fight against bladder cancer. Bladder cancer has the highest lifetime treatment costs, highlighting the significant financial burden it places on healthcare systems. Additionally, it has one of the highest recurrence rates among all cancers, underscoring the need for continuous monitoring and advanced treatment options. Furthermore, the annual supply of BCG, a primary treatment for bladder cancer, often falls short of patient demand, creating a critical gap in care.   Understanding these challenges is key to developing innovative solutions and improving patient outcomes.   #BladderCancer #Oncology #BCG

📸🎶 What a fab day out with the team! Inspired by the classic tune "Come Together," we joined forces, shared laughs, and made some unforgettable memories. Cheers to an amazing team and a day filled with fun and creativity! 🎸✨

🚀 Bladder Cancer Market Insight Series: Week 2   Welcome back to our Bladder Cancer Market Insight Series. This week, we are focusing on prevalence and the standard-of-care.   Understanding survival and recurrence rates reveals critical gaps in the lack of therapeutic options for patients living with bladder cancer – highlighting Prokarium’s innovative approach to make a meaningful impact for these patients.   Non-muscle invasive bladder cancer boasts a 5-year survival rate ranging from 71% to 96%, after treatment, yet 40-80% of patients relapse annually. Bacillus Calmette-Guérin (BCG) therapy, a live bacterial immunotherapy, has been the standard of care for high-risk patients since its FDA approval in 1990, emphasizing the need for innovation and treatment alternatives. #BladderCancer #Immunotherapy #BCG #MarketInsights

🚀 Bladder Cancer Market Insight Series: Week 1   This week, we are diving into critical statistics about bladder cancer diagnosis in the US. Did you know that bladder cancer is the 6th most common cancer? Understanding these numbers is vital for driving innovation and improving patient outcomes.   Stay tuned as we explore more insights and trends in the bladder cancer market throughout this series. Together, we can make a difference in the fight against this disease.   #BladderCancer #Oncology #CancerAwareness #MarketInsights 

✨ Thanks to everyone we connected with at SEED! ✨ Marc Biarnes Carrera, Head of Discovery, Synthetic Biology at Prokarium, had an enjoyable time at SEED, where he presented the Company's latest research poster. #SEED2024 #SyntheticBiology #Research

🚨 Prokarium at SEED 2024 🚨   Marc Biarnes Carrera, Head of Discovery, Synthetic Biology, will be presenting a poster titled Living Cures: Building a Programmable Therapeutic Platform for Optimization and Delivery of Immunostimulatory Proteins, on Wednesday the 26th June.   Drop by to learn more about our Living Cures platform. #LivingCures #SEED #SyntheticBiology

🚀 Prokarium is hiring! 🚀 We're on the lookout for talented individuals to join our innovative team. Check out our current opening and apply today: https://lnkd.in/eeFHr76q #Scientist #ResearchAssistant #Hiring #SyntheticBiology